Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2016 - 2021)

Enanta Pharmaceuticals (ENTA) has disclosed Long-Term Deferred Tax for 8 consecutive years, with $345000.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Long-Term Deferred Tax fell 97.74% year-over-year to $345000.0, compared with a TTM value of $345000.0 through Jun 2021, down 97.74%, and an annual FY2020 reading of $345000.0, down 96.96% over the prior year.
  • Long-Term Deferred Tax was $345000.0 for Q2 2021 at Enanta Pharmaceuticals, roughly flat from $345000.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $17.7 million in Q2 2017 and bottomed at $345000.0 in Q3 2020.
  • Average Long-Term Deferred Tax over 5 years is $8.5 million, with a median of $9.2 million recorded in 2018.
  • The sharpest move saw Long-Term Deferred Tax surged 203.32% in 2017, then plummeted 97.74% in 2021.
  • Year by year, Long-Term Deferred Tax stood at $7.6 million in 2017, then increased by 22.2% to $9.2 million in 2018, then rose by 15.22% to $10.7 million in 2019, then tumbled by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
  • Business Quant data shows Long-Term Deferred Tax for ENTA at $345000.0 in Q2 2021, $345000.0 in Q1 2021, and $345000.0 in Q4 2020.